Nexalin Technology (NXL) EBIT (2021 - 2026)

Nexalin Technology has reported EBIT for 6 years, with the latest figure at -$2.2 million in Q2 2026.

• On a quarterly basis, EBIT fell 38.65% year-over-year to -$2.2 million in Q2 2026; TTM through Jun 2026 was -$9.1 million, a 1.22% decrease from a year earlier, with the FY2025 full-year figure at -$8.4 million, down 8.2% from the prior year.
• EBIT was -$2.2 million for Q2 2026 at Nexalin Technology, down from -$2.1 million in the prior quarter.
• The five-year high for EBIT was -$293194.0 in Q3 2022, with the low at -$2.9 million in Q4 2024.
• Average EBIT over 5 years is -$1.6 million, with a median of -$1.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT surged 83.67% in 2022, then slumped 723.87% in 2023.
• Over 5 years, EBIT stood at -$719617.0 in 2022, then slumped by 125.74% to -$1.6 million in 2023, then slumped by 77.0% to -$2.9 million in 2024, then advanced by 16.08% to -$2.4 million in 2025, then gained by 6.87% to -$2.2 million in 2026.
• The last three EBIT figures came in at -$2.2 million (Q2 2026), -$2.1 million (Q1 2026), and -$2.4 million (Q4 2025), per Business Quant data.